PT  - JOURNAL ARTICLE
AU  - Martin J. Dahl
AU  - Mara Mather
AU  - Markus Werkle-Bergner
AU  - Briana L. Kennedy
AU  - Yuchuan Qiao
AU  - Yonggang Shi
AU  - John M. Ringman
TI  - Lower MR-indexed locus coeruleus integrity in autosomal-dominant Alzheimer’s disease is related to cortical tau burden and memory deficits
AID  - 10.1101/2020.11.16.20232561
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.11.16.20232561
4099  - http://medrxiv.org/content/early/2020/11/18/2020.11.16.20232561.short
4100  - http://medrxiv.org/content/early/2020/11/18/2020.11.16.20232561.full
AB  - Abnormally phosphorylated tau, an indicator of Alzheimer’s disease, begins to accumulate in the first decades of life in the locus coeruleus (LC), the primary source of cortical norepinephrine. Ensuing dysfunction in noradrenergic neuromodulation is hypothesized to contribute to Alzheimer’s progression. However, research into the role of the LC has been impeded by a lack of effective ways of assessing it in vivo. Advances in high-resolution brainstem magnetic resonance imaging (MRI) hold potential to investigate the association of locus coeruleus integrity and Alzheimer’s-related neuropathological markers in vivo.Leveraging a meta-analytical approach, we first synthesized LC localizations and dimensions across previously published studies to improve the reliability and validity of MR-based locus coeruleus detection. Next, we applied this refined volume of interest to determine whether MR-indexed LC integrity can serve as a marker for noradrenergic degeneration in early-onset Alzheimer’s disease. Eighteen participants (34.7±10.1 years; 9♀) with or known to be at-risk for mutations in genes associated with autosomal-dominant Alzheimer’s disease (ADAD) were investigated. Genotyping confirmed mutations in seven participants (PSEN1, n = 6; APP, n = 1), of which four were symptomatic. Participants underwent 3T-MRI, flortaucipir positron emission tomography (PET), and cognitive testing. LC MRI intensity, a non-invasive proxy for neuronal density, was semi-automatically extracted from high-resolution brainstem scans across the rostrocaudal extent of the nucleus.Relative to healthy controls, symptomatic participants showed lower LC intensity. This effect was pronounced in rostral segments of the nucleus that project to the mediotemporal lobe and other memory-relevant areas. Among carriers of ADAD-causing mutations, closer proximity to the mutation-specific median age of dementia diagnosis was associated with lower LC intensity. Leveraging a multivariate statistical approach, we revealed a pattern of LC-related tau pathology in occipito-temporo-parietal brain regions. Finally, higher locus intensity was closely linked to memory performance across a variety of neuropsychological tests.Our finding of diminished MR-indexed LC integrity in autosomal-dominant Alzheimer’s disease suggest a role of the noradrenergic system in this neurodegenerative disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMJD is recipient of a stipend from the GA. Lienert-Foundation and was supported by a stipend from the Davis School of Gerontology, University of Southern California. MM's work was supported by an Alexander von Humboldt fellowship, a Max Planck Sabbatical Award, and by National Institutes of Health (NIH) grant R01AG025340. MW-B received support from the German Research Foundation (DFG, WE 4269/5-1) and the Jacobs Foundation (Early Career Research Fellowship 2017-2019). BLK was supported by a NIH grant F32AG057162. YS was supported by NIH grants RF1AG064584 and RF1AG056573. JMR was supported by NIH grants U01AG051218, R01AG062007, and P30AG066530Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval by the University of Southern California (PI: Prof. John Ringman)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe here described LC meta mask as well as pontine reference mask is available for download on an Open Science Framework repository (osf.io/sf2ky/). All sources for previously published masks are listed in Table 1. For access to raw imaging and clinical data, please refer to the HCP (https://nda.nih.gov/ccf).https://osf.io/sf2ky/https://nda.nih.gov